
|Articles|February 24, 2010
VEGF Trap-Eye shows positive results in a phase 2 study in patients with diabetic macular oedema
VEGF Trap-Eye, the fully human, soluble VEGF receptor fusion protein that binds all forms of VEGF-A along with the related Placental Growth Factor (PIGF), has shown positive results in a Phase 2 study in patients with diabetic macular oedema (DME.
Advertisement
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
IGS 2026: Clinical pearls for detecting pre-perimetric glaucoma
2
IGS 2026: Current clinical perspectives on optic disc drusen
3
Broadening horizons: Expanding your surgical portfolio with SMILE pro for Hyperopia
4
Study finds artificial tear viscosity and shear-thinning behavior vary by formulation
5




























